5-HT3-receptor antagonists in the control of delayed-onset emesis.

Abstract

Nausea and vomiting are typical side-effects of cancer therapy. The management of acute-onset emesis (< 24 hours post-treatment) has improved markedly in recent years and the 5-HT3-receptor antagonists are widely regarded as the antiemetic 'gold standard' during this period. Delayed-onset emesis (> 24 hours post-treatment), however, still represents a therapeutic challenge. Available data indicates that the 5-HT3-receptor antagonists are at least as good as conventional antiemetics in controlling delayed-onset emesis, and that their efficacy in this setting may be improved by the addition of a corticosteroid. As a result, antiemetic guidelines recommend the addition of a 5-HT3-receptor antagonist for the treatment of delayed emesis, particularly for high-risk patients.

• Authors: Cesare Gridelli
• Journal: Anticancer research (Anticancer Res) 2003 May-Jun Vol. 23 Issue 3C Pg. 2773-82 ISSN: 0250-7005 [Print] Greece
• PMID: 12926112 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antiemetics
• Antineoplastic Agents
• Receptors, Serotonin
• Receptors, Serotonin, 5-HT3
• Serotonin Antagonists
• Ondansetron
• Granisetron

Topics

• Antiemetics (adverse effects, pharmacology, therapeutic use)
• Antineoplastic Agents (adverse effects)
• Clinical Trials as Topic
• Granisetron (adverse effects)
• Humans
• Neoplasms (drug therapy, radiotherapy)
• Ondansetron (adverse effects)
• Radiotherapy (adverse effects)
• Receptors, Serotonin (physiology)
• Receptors, Serotonin, 5-HT3
• Serotonin Antagonists (adverse effects, pharmacology, therapeutic use)
• Vomiting (etiology, prevention & control)